Clinical Research Directory

Inclusion Criteria: * NSCLC, clinical tumor stage II-IIIB * Without EGFR/ALK gene mutation * Patient 18 years or older. * Scheduled for neoadjuvant immunotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 * Life expectancy ≥ 12 weeks. * Patient able to understand and sign written informed consent. Exclusion Criteria: * With other cancers (excluding NSCLC or skin cancer other than melanoma, or cancers treated curatively with follow up of more than 5 years without recurrence). * With history of chemotherapy or radiotherapy (including pre - operative and post - operative adjuvant chemotherapy and radiotherapy) or systemic anti - tumor treatment. * with autoimmune diseases unsuitable for PD - 1 monoclonal antibody treatment, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain - Barré syndrome, or multiple sclerosis. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.